Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Merck
Mallinckrodt
Johnson and Johnson

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NABILONE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Nabilone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00272207 A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Valeant Canada Limited Phase 2 2006-04-01 The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.
NCT00272207 A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Winnipeg Regional Health Authority Phase 2 2006-04-01 The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.
NCT00381199 Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia Completed McGill University Health Center N/A 2006-04-01 Most chronic pain patients with insomnia are currently not well-managed using existing medications. If found to safely improve sleep with chronic pain patients, nabilone could be added to the treatment options available in the management of fibromyalgia and associated symptoms. The principle hypothesis of this study is that nabilone at a dose of 0.5-1mg is as efficacious as amitriptyline at a dose of 10-20mg, in improving sleep quality in patients with fibromyalgia.
NCT00384410 Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients Unknown status Valeant Pharmaceuticals International, Inc. Phase 2 2005-12-01 Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nabilone

Condition Name

Condition Name for Nabilone
Intervention Trials
Parkinson Disease 3
Fibromyalgia 2
Pain 2
Neuropathic Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nabilone
Intervention Trials
Neuralgia 4
Marijuana Abuse 3
Parkinson Disease 3
Fibromyalgia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nabilone

Trials by Country

Trials by Country for Nabilone
Location Trials
Canada 13
United States 5
Austria 2
Mexico 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nabilone
Location Trials
New York 3
Maryland 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nabilone

Clinical Trial Phase

Clinical Trial Phase for Nabilone
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nabilone
Clinical Trial Phase Trials
Completed 9
Recruiting 7
Not yet recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nabilone

Sponsor Name

Sponsor Name for Nabilone
Sponsor Trials
University of Manitoba 4
Valeant Canada Limited 3
New York State Psychiatric Institute 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nabilone
Sponsor Trials
Other 26
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
AstraZeneca
Express Scripts
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.